RxSight (NASDAQ:RXST) Price Target Increased to $61.00 by Analysts at Oppenheimer

RxSight (NASDAQ:RXST – Get Free Report) had its target price raised by Oppenheimer from $54.00 to $61.00 in a research report issued on Thursday, Benzinga reports. The firm presently has an “outperform” rating on the stock. Oppenheimer’s price objective points to a potential upside of 8.73% from the company’s previous close. Several other equities analysts […]

Related Keywords

United States ,Stifel Nicolaus ,Robert Keith Warner ,Eric Weinberg ,Advisors Inc ,Bluepath Capital Management ,Securities Exchange Commission ,Steward Partners Investment Advisory ,Morgan Stanley ,Riverpark Advisors ,Needham Company ,Wells Fargo Company ,Rxsight Inc ,Get Free Report ,Wells Fargo ,Director Robert Keith Warner ,Exchange Commission ,Park Advisors ,Partners Investment Advisory ,Path Capital Management ,Rxsight Daily ,Rxsight ,Nasdaq Rxst ,Rxst ,Medical ,Boost Price Target ,Oppenheimer Holdings Inc ,